This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Warburg Pincus buys Mumbai’s pharma company Integrace in Rs 1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bWKc1ym
via IFTTT

Jitendra Singh releases Rs 1,500 crore under third phase of Biomedical Research Career Programme

Union Minister Jitendra Singh released fifteen hundred crore rupees for the Biomedical Research Career Programme. This funding supports outstanding biomedical researchers and promotes collaborative research initiatives. The program, initiated in two thousand eight, has supported over five hundred researchers. It has also strengthened research across more than two hundred institutions nationwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JrUtK9b
via IFTTT

Warburg Pincus buys Mumbai’s pharma company Integrace in ₹1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xiPgYI4
via IFTTT

Sun Pharma gets SAHPRA approval for generic semaglutide injection in South Africa for type 2 diabetes

South Africa's regulator approved Sun Pharma's generic semaglutide injection for diabetes. This approval allows marketing to supplement diet and exercise for adults. The company plans to launch the product soon in injectable pens. South Africa is the second market after India for this approval. This reflects Sun Pharma's commitment to improving access to generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S7kuYoN
via IFTTT

OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars

OneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSource providing integrated manufacturing capabilities for biosimilars. The partnership aims to expand access to high-quality, affordable biologics for patients globally. Formycon AG CEO stated this strengthens their supply capabilities with a quality-focused partner. Both companies aim to broaden sustainable global access to life-changing biosimilar therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EtkJz94
via IFTTT

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows patients to self-administer injections, improving access. Previously, patients received intravenous infusions, typically at clinics, for initial treatment. This approval differentiates Leqembi from competitor Kisunla's infusion-only requirement. The drug targets amyloid beta plaques in the brains of Alzheimer's patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oj2OFg0
via IFTTT

Warburg, Bain, CVC among PE firms in talks to buy into Agappe Diagnostics

Several global private equity firms are exploring a significant stake purchase in Agappe Diagnostics. This potential deal involves both existing investor sales and new capital infusion. The transaction is expected to value the Kochi-based in-vitro diagnostics firm at over three thousand crore rupees. Agappe Diagnostics develops and manufactures diagnostic reagents and equipment for global markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GAwaOnq
via IFTTT